Scarica l'app Stockscreener
98.60
2.85%
-2.89
Pre-mercato:
99.99
1.39
+1.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$101.49
Aprire:
$101.25
Volume 24 ore:
2.90M
Relative Volume:
0.79
Capitalizzazione di mercato:
$21.37B
Reddito:
$819.56M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-17.17
EPS:
-5.7434
Flusso di cassa netto:
$-951.64M
1 W Prestazione:
-7.78%
1M Prestazione:
-7.52%
6M Prestazione:
-37.15%
1 anno Prestazione:
-8.09%
Intervallo 1D:
$97.05
$101.91
Intervallo di 1 settimana:
$97.05
$107.37
Portata 52W:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
98.60 | 22.70B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2026-03-30 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Cantor Fitzgerald reiterates Insmed stock rating on Brensupri sales outlook By Investing.com - Investing.com Canada
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo Finance
Insmed Inc (INSM) Institutional Confidence - TradingKey
Insmed Inc (INSM) Cash Flow - TradingKey
Insmed Inc (INSM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insmed Inc (INSM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Insmed Inc (INSM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insmed Inc (INSM) Income Statement - TradingKey
INSM|Insmed Inc|Price:104.760|Chg%:+0.030 - TradingKey
Insmed Incorporated Revenue Breakdown – NASDAQ:INSM - TradingView
Insmed chair and CEO William Lewis sells over $1.1m in company stock - Investing.com Australia
INSM|Insmed Inc|Price:106.920|Chg%:-0.490 - TradingKey
Form 4 Insmed Inc For: 24 July By Investing.com - Investing.com Canada
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
Insmed Incorporated Revenue Breakdown – LSE:0JAV - TradingView
Insmed Inc. CEO William Lewis Executes Key Stock Option Acquisitions and Share Sales - Kalkine Media
Insmed (INSM) CEO trades 10,700 shares after option exercise - Stock Titan
Concerns Over the Pace of its Brinsupri’s Launch Hurt Insmed (INSM) - Yahoo Finance
Insmed and Ty Pennington team up - WFLA
Form 144 INSMED INC For: 24 July - Investing.com UK
Form 144 INSMED INC For: 24 July By Investing.com - Investing.com South Africa
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INSMED INC (INSM.MX) Q1 FY2026 earnings call transcript - Yahoo Finance
Insmed (INSM) insider William Lewis plans 10,700-share stock sale - Stock Titan
William Haggerty Joins Insmed Incorporated as Senior Director of People Operations - hrtoday.in
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), TransMedics Group (TMDX) and Hims & Hers Health (HIMS) - The Globe and Mail
Insmed's second-quarter business update will be webcast Aug. 6 - Stock Titan
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Guggenheim Reaffirms Their Buy Rating on Insmed (INSM) - The Globe and Mail
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
JPMorgan Chase & Co. (INSM) reports 10.37M Insmed shares, a 4.7% stake - Stock Titan
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $207 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
INSM Initiated Coverage by BMO Capital -- Price Target Announced at $192 - GuruFocus
BMO Capital Initiates Insmed at Outperform With $192 Price Target - marketscreener.com
Is Insmed (INSM) Priced Too Richly For Its Phase 3 Progress? - Yahoo Finance
Insmed (INSM) Following TPIP 12 Month Data, Does The Valuation Still Stack Up - Yahoo Finance
BMO initiates Insmed stock with outperform rating on respiratory franchise potential - Investing.com Nigeria
Insmed Announces Positive 12-Month Data from OLE Study of Inhalation Solution for Pulmonary Arterial Hypertension - dicardiology.com
Positive 12‑Month TPIP PAH Data Could Be A Game Changer For Insmed (INSM) - Yahoo Finance
Buy Insmed for a double, this analyst says - Cantech Letter
Investors’ Concerns Hurt Insmed Incorporated (INSM) Despite Better-Than-Expected Results - Yahoo Finance
Insmed stock price target maintained at $220 by H.C. Wainwright - Investing.com Canada
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3 - webull.com
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237 - Moomoo
Open-label extension drives home benefits of Insmed’s PAH therapy - BioWorld News
Stifel Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $200 - Moomoo
Insmed stock price target maintained at $200 by Stifel on trial data - Investing.com Canada
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning - Benzinga
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Jul 23 '26 |
Sale |
106.06 |
10,700 |
1,134,890 |
259,058 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):